RUNX1 and acute myeloid leukemia: Furthermore, our mouse t(8;21) AML models will provide ideal platforms to perform the in vivo CRISPR/Cas9 library screening to identify key regulators that promote or suppress the development of RUNX1-ETO leukemia, particularly in vivo.